Clinical use of lenvatinib in patients with previous renal and/or hepatic impairment and radioiodine‐refractory differentiated thyroid cancer

Autor:	Javier Martínez‐Trufero
Jazyk:	angličtina
Rok vydání:	2022
Předmět:	hepatotoxicity lenvatinib radioiodine refractory differentiated thyroid carcinoma renal impairment Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	Cancer Medicine, Vol 11, Iss S1, Pp 5-9 (2022)
Druh dokumentu:	article
ISSN:	2045-7634
DOI:	10.1002/cam4.5130
Popis:	Abstract Lenvatinib is one the most active drugs in radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) such that it has become an important therapeutic tool in tumor control and survival. Renal and hepatic impairments are common comorbidities in cancer patients. Treating these patients is a challenge that requires careful consideration. As a first approach to patients with RR‐DTC and renal or hepatic impairment, Summary of Product Characteristics recommendations for lenvatinib use and dose adjustments should be strictly followed. Close clinical and blood monitoring is the gold standard approach to optimizing lenvatinib's use during the whole course of treatment.
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/1ef3bcaa1b744c34bccd3fa37175b359 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.